| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Dimitrios P. Bogdanos | Q48362185 |
| P2093 | author name string | Efterpi Zafiriou | |
| Lazaros I Sakkas | |||
| P2860 | cites work | Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis | Q28208761 |
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
| Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. | Q48770670 | ||
| Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. | Q49335379 | ||
| Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis | Q49824739 | ||
| Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. | Q50034719 | ||
| Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints | Q50099588 | ||
| Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. | Q50906224 | ||
| Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial. | Q51730950 | ||
| Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. | Q52650418 | ||
| Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. | Q53125208 | ||
| Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. | Q54261377 | ||
| Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. | Q54978927 | ||
| Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials | Q57159144 | ||
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials | Q57210849 | ||
| Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review | Q57456661 | ||
| Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial | Q58113059 | ||
| Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases | Q58566180 | ||
| Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial | Q58582257 | ||
| Tildrakizumab for the treatment of psoriasis | Q58614044 | ||
| Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor in | Q58759049 | ||
| Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis | Q58992083 | ||
| Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective | Q59337044 | ||
| Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study | Q59790112 | ||
| Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis | Q61806742 | ||
| Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry | Q61820983 | ||
| A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis | Q61853646 | ||
| Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials | Q62633603 | ||
| Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial | Q85410950 | ||
| Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study | Q89074034 | ||
| Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials | Q91198175 | ||
| Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs | Q91438247 | ||
| Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis | Q91923632 | ||
| Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis | Q92061008 | ||
| Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis | Q93000179 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) | Q28280465 | ||
| Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin | Q28301222 | ||
| IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis | Q28587556 | ||
| Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation | Q29614224 | ||
| Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla | Q30760660 | ||
| Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. | Q31133026 | ||
| First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis | Q33593625 | ||
| Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas | Q33659249 | ||
| Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice | Q34144256 | ||
| Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio | Q34538249 | ||
| Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? | Q34937925 | ||
| Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo | Q35091158 | ||
| Regulation of inflammatory responses by IL-17F | Q36639980 | ||
| The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses | Q37040371 | ||
| Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a | Q37346670 | ||
| Th17 and Th22 cells in psoriatic arthritis and psoriasis | Q37689670 | ||
| Signaling of interleukin-17 family cytokines in immunity and inflammation | Q37815900 | ||
| IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. | Q38539817 | ||
| Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa | Q38558538 | ||
| Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 | ||
| Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38989105 | ||
| Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis | Q39238937 | ||
| Interleukin 17 is a chief orchestrator of immunity | Q39314776 | ||
| The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex | Q39953231 | ||
| Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial | Q40196632 | ||
| A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. | Q40821601 | ||
| Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis | Q40973506 | ||
| The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis | Q41620801 | ||
| IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis | Q41975379 | ||
| Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis | Q42508679 | ||
| Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial | Q44525441 | ||
| IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells | Q46043893 | ||
| Psoriasis prevalence among adults in the United States | Q46308366 | ||
| Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. | Q47148249 | ||
| Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. | Q47236145 | ||
| Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation | Q47253021 | ||
| Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis | Q47633796 | ||
| Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors | Q47633814 | ||
| Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). | Q47792431 | ||
| Psoriasis pathogenesis and the development of novel targeted immune therapies. | Q47830025 | ||
| First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. | Q48115736 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 872 | |
| P577 | publication date | 2019-08-06 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis | |
| P478 | volume | 10 |
Search more.